To externally validate the STAR-CAP prognostic system for prostate cancer (PCa) and compare it to the CAPRA score to predict for biochemical recurrence (BCR) after radiation therapy (RTx).
We included patients treated with RTx between 2002 and 2021 for non-metastatic PCa at our institution.